Physician profile
Michael Simhachalam
NPI 1841857331
$1,444.44
in general payments reported to CMS, 2019-2025
23 companies · $409 in 2025
The $409 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $77.49 · 2022: $28.93 · 2023: $298 · 2024: $632 · 2025: $409.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,338.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,338.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $182.19 | 2023-2025 | |
| Novo Nordisk INC | $148.30 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $141.24 | 2023-2025 | Vraylar, Linzess, Viberzi |
| Bioventus LLC | $127.94 | 2021-2025 | Gelsyn-3 |
| Lilly USA, LLC | $124.39 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Exact Sciences Corporation | $120.43 | 2023-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $91.58 | 2024-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $90.97 | 2024-2025 | Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $86.91 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $55.23 | 2024-2025 | |
| Amgen INC. | $35.86 | 2024 | Evenity, Prolia, Repatha |
| Astellas Pharma US INC | $31.61 | 2023-2024 | Myrbetriq, Veozah |
| Neurocrine Biosciences, INC. | $25.97 | 2024 | Ingrezza |
| Dexcom, INC. | $25.21 | 2024 | Dexcom G6 Transmitter |
| Axsome Therapeutics, INC. | $21.50 | 2024 | Auvelity |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Irhythm Technologies, INC. | $21.48 | 2024 | Zio Xt Patch, Zio Monitor |
| Lundbeck LLC | $18.29 | 2025 | Rexulti |
| Ge Healthcare | $17.03 | 2021 | |
| Sanofi-Aventis U.S. LLC | $16.51 | 2023 | |
| Shield Therapeutics INC | $16.17 | 2024 | |
| Cranial Technologies, INC | $16.14 | 2024 | Doc Band |
| Merck Sharp & Dohme LLC | $14.80 | 2023 | Belsomra |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.69 | 2025 | Caplyta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Simhachalam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.